Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Yescarta to Join NHI Price List on April 21, Gets CEA-Tweak from Get-Go
Daiichi Sankyo’s CAR-T cell therapy Yescarta (axicabtagene ciloleucel) will be added to the NHI reimbursement list on April 21, with a price worked out based on Novartis’ first-in-class Kymriah (tisagenlecleucel), which just came out of its cost-effectiveness assessment (CEA) with…
To read the full story
Related Article
- Japan Officially Announces CEA-Based Prices for Kymriah/Trelegy, Effective July 1
April 21, 2021
- Kymriah to Get 4.3% Reduction, Trelegy 0.5% Cut in 1st CEA-Based Price Tweak
April 14, 2021
- Kymriah to Face 4% Price Cut in 1st CEA-Based Price Tweak, Yescarta Too
April 13, 2021
- Yescarta Approved in Japan as 2nd CAR-T Cell Therapy
January 22, 2021
REGULATORY
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
- 3 Label Expansions Get NHI Coverage on Public Knowledge Pathway
July 29, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…